Radiolabeled styrylpyridines and pharmaceutical compositions thereof

Abstract

The invention discloses radiopharmaceutical composition of Fluorine-18 (F18) labelled styrylpyridine compounds, for use as a medicament for the treatment or diagnosis of a disease or condition associated with build-up of amyloid-β (Aβ) aggregates, preferably F18 Florbetapir, that is free of undesirable nitrosamine drug substance related impurities (NDSRI) and other undesirable nitrosamine impurities. The invention further relates to polymorphic forms of precursors of F18 Florbetapir and their use for preparing F18 Florbetapir.

Dependencies are inferred from the claim text.